The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis

Abstract

BackgroundMicroRNA-34a (miR-34a) is a master regulator of tumor suppression in breast cancer (BC). This systematic review aims to analyze the diagnostic accuracy of miR-34a in the detection of BC as a biomarker.ResultsA total of 1858 BC cases and 494 controls from thirteen eligible studies reported in 9 publications were included. The overall pooled sensitivity, specificity, negative likelihood ratio (NLR), positive likelihood ratio (PLR), and diagnostic odds ratio (DOR) were 85.50% (95% CI: 83.80-87.00%), 70.00% (95% CI: 65.80–74.10%), 0.29 (95% CI: 0.19–0.43), 2.58 (95% CI: 1.91–3.43), and 9.39 (95% CI: 5.47–16.12), respectively. Similarly, the overall area under the curve (AUC) of the summary receiver operating characteristic (SROC) was 0.80, indicating the high conservation of miR-34a as a biomarker. Furthermore, subgroup analysis suggested that the use of miR-34a as a biomarker is more accurate in tissue-based sample of invasive BC. We also indicated that miR-34a is a capable biomarker in diagnosing BC in people of Caucasian descent.Materials and MethodsA systematic search was conducted for eligible publications that address miR-34a expression level in BC cases and noncancerous controls. Diagnostic capacity of miR-34a for BC was assessed using pooled sensitivity and specificity, DOR, and AUC of SROC. PLR and NLR were verified to estimate the miR-34a diagnostic accuracy in clinical level. The quality of the included studies was assessed by QUADAS-2.ConclusionsThese findings suggest miR-34a is a promising non-invasive biomarker in diagnosing BC. Well-designed cohort studies should be implemented to warrant the diagnostic value of miR-34a in clinical purposes.

Delphinidin suppresses breast carcinogenesis through the HOTAIR/microRNA‐34a axis

“…miR‐34a, regarded as a tumor suppressor, is decreased in breast cancer cell lines and tissues . In the current study, we detected that the level of miR‐34a was decreased in breast and tumor tissues in MNU‐treated rats, and that delphinidin treatment effectively upregulated the level of miR‐34a in tumor tissues.…”

Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion

“…In this study, we found that miR-34a expression was significantly lower in TNBC cells compared with normal breast epithelium and that this lower expression was significantly associated with shorter overall patient survival, indicating that miR-34a is a prognostic factor in patients with TNBC. In addition, Imani and colleagues showed that miR-34a inhibits TWIST1, ZEB1, and NOTCH1 expression through binding to their 3 0 -UTR and reduces the metastatic and invasive features of metastatic breast cancer (34,35). The TP53 gene (encoding the p53 protein), which is mutated in about 50% of human cancers and 84% of TNBC tumors (36), was shown to induce miR-34, which turned out to be direct p53 target genes (37).…”

miR-34a regulates adipogenesis in porcine intramuscular adipocytes by targeting ACSL4

“…MicroRNA-34a has attracted interest recently because of its ability to modulate a myriad of oncogenic functions in different cancers [21][22][23][24][25][26][27]. Not only does it play a role in cancer metastasis [28,29] and drug resistance [30], it is now being evaluated as a diagnostic as well as a prognostic biomarker [31][32][33]. In addition, a miR-34a inhibitor has been identified that may effectively protect against sevoflurane-induced hippocampal apoptosis by targeting Wnt1 and activating the Wnt/β-catenin pathway [34].…”